Table 2. Univariate analysis and Cox proportional hazard model for the primary outcome (major arrhythmic events).
| Univariate analysis | Multivariate analysis | |||||
|---|---|---|---|---|---|---|
| HR | 95%CI | p | HR | 95%CI | p | |
| Galectin-3 (for each 1 ng/mL) | 1.003 | 0.97–1.04 | 0.877 | |||
| Galectin-3>22.5 ng/mL | 1.13 | 0.47–2.70 | 0.787 | |||
| Atrial fibrillation | 1.86 | 0.75–4.60 | 0.182 | |||
| LVEF<20% | 0.69 | 0.21–2.30 | 0.691 | |||
| LVEDD>73 mm | 4.13 | 1.91–8.90 | <0.001 | 3.70 | 1.69–8.1 | 0.001 |
| Peak VO2<14.2 mL/kg/min | 1.69 | 0.75–3.90 | 0.203 | |||
| VE/VCO2 slope>48.4 | 2.32 | 1.05–5.10 | 0.037 | |||
| EPB | 3.37 | 1.52–7.40 | 0.030 | 2.67 | 1.19–6.0 | 0.017 |
| HV interval>59 ms | 2.23 | 1.01–4.90 | 0.047 | |||
| NSVT>8 beats | 3.27 | 1.11–9.70 | 0.030 | 3.47 | 1.15–10.5 | 0.027 |
| Positive EPS | 1.58 | 0.54–4.60 | 0.403 | |||
| Elevated natriuretic peptides | 2.75 | 1.26–6.01 | 0.011 | |||
HR: hazard ratio; LVEF: left ventricular ejection fraction; LVEDD: left ventricular end-diastolic diameter; peak VO2: peak oxygen consumption; NSVT: non-sustained ventricular tachycardia; EPB: exercise periodic breathing; EPS: invasive electrophysiological study.